Development and testing of Streptococcus pneumoniae conjugate vaccines

Clinical Microbiology and Infection

Volumn 5, Issue SUPPL. 4, 1999, Pages

  Klein, David L ^a,c   Eskola, Juhani ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE;

ANTIBODY PRODUCTION; ANTIBODY TITER; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; META ANALYSIS; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 18844481480     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1999.tb00853.x     Document Type: Conference Paper

References (51)

1. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR 1997; 47(No. RR-8)
2. Mufson M. Streptococcus pneumoniae. In Mandell GL, Douglas RG, Bennett JE eds. Principles and practices of infectious disease. Churchill Livingston, 1990; 1539-50.
3. Leowski J. Mortality from acute respiratory infections in children under 5 years of age: global estimates. World Health Stat Q 1986; 39: 138-44.
4. WHO Technical Advisory Group on ARI. A program for controlling acute respiratory infections in children: memorandum from a WHO meeting. Bull WHO 1984; 64: 47-58.
5. Gray BM, Dillon HC Jr. Clinical and epidemiological studies of pneumococcal infection in children. Pediatr Infect Dis 1986; 5: 201-7.
6. Klein JO. The epidemiology of pneumococcal disease in infants and children. Rev Infect Dis 1981; 3: 246-53.
7. Hofmann J, Cetron MS, Parley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 333: 481-6.
8. Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis 1997; 24(suppl 1): S85-8.
9. Deka K, Ware JC, Chonmaitree T, et al. Penicillin-resistant Streptococcus pneumoniae: in acute otitis media: prevalence, serotypes, and clinical significance. In Lim DJ, Bluestone CD, Casselbrant M, Klein JO, Ogra PL, eds. Proceedings of the Sixth International Symposium on Recent Advances in Otitis Media. Hamilton, Canada: BC Decker Inc. 1996: 303-5.
10. Sih T. Drug-resistant Streptococcus pneumoniae. In Lim DJ, Bluestone CD, Casselbrant M, Klein JO, Ogra PL, eds. Proceedings of the Sixth International Symposium on Recent Advances in Otitis Media. Hamilton, Canada: BC Decker Inc., 1996: 305-7.
11. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol. 1995; 33: 2759-62.
12. Kayhty H, Eskola J. New vaccines for the prevention of pneumococcal infections. Emerg Infect Dis. 1996; 2: 289-95.
13. Siber GR. Pneumococcal disease: prospects for a new generation of vaccines. Science 1994; 265: 1385-7.
14. Stein KE. Network regulation of the immune response to bacterial polysaccharide antigens. Curr Top Microbiol Immunol. 1985; 119: 57-74.
15. Murphy TV. Vaccines for Haemophilus influenzae type b. Semin Pediatr Infect Dis 1991; 2: 120-34.
16. Beuvery ECF, van Rossum F, Nagle J. Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates. Infect Immun 1982; 37: 15-22.
17. Chu C, Schneerson R, Robbins JB, Rastogi SC. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun 1983; 40: 245-56.
18. Gordon LK. Characterization of a hapten-carrier conjugate vaccine: H. influenzae-diphtheria conjugate vaccine. In Chanock RM, Lerner RA (eds), Modern approaches to vaccines. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 1984; 393-6.
19. Robbins JB, Schneerson R. Polysaccharide-protein conjugates: new generation vaccines. Rev Infect Dis 1990; 161: 821-32.
20. Butler JC, Dowell SF, Breiman RF. Epidemiology of emerging pneumococcal drug resistance: implications for treatment and prevention. Vaccine 1998; 16: 1693-7.
21. Käyhty H, Eskola J. New vaccines for the prevention of pneumococcal infections. Emerg Infect Dis 1996; 2: 289-98.
22. Åhman H, Käyhty H, Lehtonen H, et al. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr Infect Dis J 1998; 17: 211-16.
23. Obaro SK, Huo Z, Banya WAS, et al. A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children. Pediatr Infect Dis J 1997; 16: 1135-40.
24. Powers DC, Andorson EL, Lottenbach K, Mink CM. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis 1996; 173: 1014-18.
25. Shelly MA, Jacoby H, Riley GJ, et al. Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect Immun 1997; 65: 242-7.
26. Storek J, Mendelman PM, Witherspoon RP, et al. IgG response to pneumococcal polysaccharide-protein conjugate appears similar to IgG response to polysaccharide in bone marrow transplant recipients and healthy adults. Clin Infect Dis 1997; 25: 1253-5.
27. Nieminen T, Kayhty H, Virolainen A, Eskola J. Circulating antibody secreting cell response to parenteral pneumococcal vaccines as an indicator of a salivary IgA antibody response. Vaccine 1997; 16: 313-19.
28. Granoff DM, Lucas AH. Laboratory correlates of protection against Haemophilus influenzae type b disease. Importance of assessment of antibody avidity and immunological memory. Ann NY Acad Sci 1995; 745: 278-88.
29. Anttila M, Eskola J, Ahinan H, Käyhty H, et al. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 1998; 177: 1614-21.
30. Schlesinger Y, Granoff DM. Vaccine Study Group. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. JAMA 1992; 267: 1489-94.
31. Hidalgo H, Moore C, Leiva L, Sorensen RU. Pre- and postpneumococcal antibody titers in children with recurrent infections. Ann Allergy Asthma Immunol 1996; 76: 341-6.
32. Sorensen RU, Leiva LE, Giangrosso PA, et al. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J 1998; 17: 685-91.
33. Chan CY, Molrine DC, George S, et al. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 1996; 173: 256-8.
34. King JC Jr, Vink PE, Chang I, et al. Antibody titers eight months after three doses of a five-valent pneumococcal conjugate vaccine in HIV and non-HIV-infected children less than two years of age. Vaccine 1998; 16: 361-5.
35. Dagan R, Givon N, Yagupsky P, et al. Effect of a 9-valent pneumococcal vaccine conjugated to CRM197 (PncCRM9) on nasopharyngeal (NP) carriage of vaccine type and non-vaccine type 5. pneumoniae (Pnc) strains among day care center (DCC) attendees [abstract G-52]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA. Washington, DC: American Society for Microbiology, 1998: 299.
36. Obaro SK, Adegbola RA, Banya WA, Greenwood BM. Carriage of pneumococci after pneumococcal vaccination. Lancet 1996; 348: 271-2.
37. Klugman KP. Conjugate pneumococcal vaccine: current and future role. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada. Washington, DC: American Society for Microbiology, 1997: 395.
38. Black S, Shinefield H, Ray P, et al. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: results of the Northern California Kaiser Permanente Efficacy Trial [abstract LB-9]. In: Program and abstracts (addendum) of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA. Washington DC: American Society for Microbiology, 1998: 23.
39. 197 in United States infants. Pediatrics 1998; 101: 604-11.
40. Fedson DS. Influenza and pneumococcal vaccination of the elderly: newer vaccines and prospects for clinical benefits at the margin. Prev Med 1994; 23: 751-5.
41. Schutze M-P, Leclerc C, Jolivet TM, et al. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol 1985; 135: 2319-22.
42. Peeters CCAM, Tenbergen-Meekers A-M, Poolman JT, et al. Effect of carrier priming on immunogenicity of saccharideprotein conjugate vaccine. Infect Immun 1991; 59: 3504-10.
43. Nesin M, Ramirez M, Tomasz A. Capsular transformation of a multidrug-resistant Streptococcus pneumoniae in vivo. J Infect Dis 1998; 177: 707-13.
44. Lock RA, Paton JC, Hansman D. Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against Streptococcus pneumoniae. Microb Pathog 1988; 5: 461-7.
45. Tart RC, McDaniel LS, Ralph BA, Briles DE. Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis 1996; 173: 380-6.
46. Sampson JS, O'Connor SP, Stinson AR, Tharpe JA, Russell H. Cloning and nucleotide sequence analysis of psaA, the Streptococcus pneumoniae gene encoding a 37-kilodalton protein homologous to previously reported Streptococcus sp. adhesins. Infect Immun 1994; 62: 319-24.
47. Alexander JE, Lock RA, Peeters C, et al. Immuniration of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneutnoniae. Infect Immun 1994; 62: 5683-8.
48. Canvin JR, Marvin AP, Sivakumaran M, et al. The role of pneumolysin and autolysin in the pathology of pneumonia and septicemia in mice infected with a type 2 pneumococcus. J Infect Dis 1995; 172: 119-23.
49. McDaniel LS, Sheffield JS, Delucchi P, Briles DE. PspA, a surface protein of Streptococcus pneutnoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun 1991; 59: 222-8.
50. Briles DE, Hollingshead SK, Swiatlo E, et al. PspA and PspC: their potential for use as pneumococcal vaccines. Microb Drug Resist 1997; 3: 401-8.
51. Klein DL. Pneumococcal conjugate vaccines: review and update. Microb Drug Resist 1995; 1: 49-58.